CONMED Corporation
Last updated September 27, 2026
Organization details
- Legal name
- CONMED Corporation
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- CNMD
- Primary stock exchange
- NYSE
Identifiers
- SEC CIK
- 0000816956
Board of directors
-
Barbara J. Schwarzentraub · DirectorSince 2023
-
Brian Concannon · DirectorSince 2023
-
Celine Christine Martin · DirectorSince 2026
-
Charles Farkas · DirectorSince 2023
-
Curt R. Hartman · Director · President and CEOSince 2023
-
David M. Bronson · DirectorSince 2023
-
Jeffrey B. Mirviss · DirectorSince 2026
-
Jerome J. Lande · DirectorSince 2023
-
John L. Workman · DirectorSince 2023
-
Kim Kelderman · DirectorSince 2025
-
LaVerne H. Council · DirectorSince 2023
-
Mark Kaye · DirectorSince 2025
-
Martha Goldberg Aronson · DirectorSince 2023
Chief executives
Curt R. Hartman
· President, CEO and Chair
Dates unknown
Board connections
6 of this board's directors also sit on 6 other boards.
- via Kim Kelderman
- via LaVerne H. Council
- via John L. Workman
- via Celine Christine Martin
- via Jerome J. Lande
- via Martha Goldberg Aronson
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $161,091
- 2 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 2, 2026 | David M. Bronson Director | Option exercise | +668 | — | — |
| Jun 2, 2026 | LaVerne H. Council Director | Option exercise | +668 | — | — |
| Jun 2, 2026 | Charles Farkas Director | Option exercise | +668 | — | — |
| Jun 2, 2026 | Mark Kaye Director | Option exercise | +668 | — | — |
| Jun 2, 2026 | Barbara J. Schwarzentraub Director | Option exercise | +668 | — | — |
| Mar 6, 2026 | Lalomia Brent Officer (Executive VP RA, QA) | Option exercise | +75 | — | — |
| Mar 6, 2026 | Lalomia Brent Officer (Executive VP RA, QA) | Shares withheld for tax | −26 | $39.90 | $1,037 |
| Feb 24, 2026 | Mark Kaye Director | Option exercise | +152 | — | — |
| Dec 31, 2025 | Lalomia Brent Officer (Executive VP RA, QA) | Other | +32 | $40.60 | $1,284 |
| Nov 21, 2025 | Glaze Richard Officer (Chief Information Officer) | Open-market sale | −257 | $41.21 | $10,591 |
| Nov 20, 2025 | Glaze Richard Officer (Chief Information Officer) | Option exercise | +375 | — | — |
| Nov 20, 2025 | Glaze Richard Officer (Chief Information Officer) | Shares withheld for tax | −118 | $40.63 | $4,794 |
| Nov 6, 2025 | Garner Todd W Officer (Executive Vice President & CFO) | Open-market sale | −3,500 | $43.00 | $150,500 |
| Nov 4, 2025 | Foust Hollie K Officer (General Counsel & Corp Sec) | Option exercise | +4,000 | — | — |
| Nov 4, 2025 | Foust Hollie K Officer (General Counsel & Corp Sec) | Shares withheld for tax | −1,114 | $45.71 | $50,921 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.